GENinCode – “Approval of CARDIO inCode-score in New York state”. Er, what about the balance sheet position now after its February fundraise?
‘Predictive genetics’ company GENinCode (GENI) has announced “Approval of CARDIO inCode-score in New York state”, noting that “enables full state coverage under US Centers for Medicare and Medicaid Services with the test included in the 2025 Clinical Laboratory Fee Schedule at an average reimbursement of ~$500.00 per test”. What about this currently helping the shares approaching 40% higher to 3p?
